Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on ProQR Therapeutics (NASDAQ:PRQR) and raises the price target from $2 to $2.5.
March 14, 2024 | 10:27 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on ProQR Therapeutics and raises the price target from $2 to $2.5.
The upgrade in price target by a reputable analyst suggests a positive outlook on the stock, likely leading to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100